Overview

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

Status:
Completed

Trial end date:
2005-10-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca